28
Jan
2010
Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - HIF, X - Oncology
Elara Pharmaceuticals (Germany) a preclinical-stag biopharma focused on Hypoxia Inducible Factor antagonizing drugs for the treatment of different cancers, closed a $3.6M Series A financing. Participants include EMBL Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb